Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Amsterdam Molecular Therapeutics’ Glybera(R) Significantly Reduces the Risk of Pancreatitis in LPLD Patients

June 28, 2011 By Bio-Medicine.Org

AMSTERDAM, June 29, 2011 /PRNewswire/ —

Data Presented at the
79
thEuropean Atherosclerosis
Society Meeting

Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in
the field of human gene therapy, today released data showing that
its gene therapy Glybera® (alipogene tiparvovec) significantly
reduces the risk of pancreatitis in patients with Lipoprotein
Lipase Deficiency (LPLD). Pancreatitis, or inflammation of the
pancreas, is a major clinical symptom of LPLD. It causes severe
abdominal pain and often leads to hospitalization of patients as
well as other complications such as diabetes and early
atherosclerosis. Data were presented at the 79th
European Atherosclerosis Society Meeting (26-29 June 2011,
Gothenburg, Sweden).

“These data demonstrate the dramatic impact Glybera can have in
the lives of LPLD patients. Pancreatitis is a debilitating and
extremely painful condition. Many patients end up in the hospital
emergency room and try to control the pain by any means,” explained
Janneke de Wal, Director of Global Sales & Marketing at AMT.
“By reducing the incidence of pancreatitis episodes, Glybera has
the potential to help “normalize” the day to day lives of patients
affected by this disease and prevent the often frequent trips to
hospital.”

Study Details

Historical data on hospital presentations due to abdominal pain
from 17 patients already treated with Glybera were collected in
this case control study. Blinded event assessment was done by an
expert adjudication committee using a modified Atlanta Diagnostic
Criteria for acute pancreatitis to allow for incomplete historical
data. A statistically significant (p=0.0434) reduction in the risk
of acute pancreatitis was seen when the period from the first
pancreatitis event to administration of Glybera was compared with
the post-therapy period (median = 2.9 years). The hazard ratio, a
measure of how o

‘/>”/>

SOURCE

Related Articles Read More >

Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial
CeQur Simplicity
CeQur is launching a discreet, convenient ‘wearable insulin pen’

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech